Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade, plus Revlimid, plus ...

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development.

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients Paris, December 9, 2024. New data from three oral presentations, which demonstrated ...

Sanofi (SNY) says new data from three oral presentations demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma patients. Sarclisa-VRd ...

Isatuximab is under clinical development by Sanofi and currently in Phase II for Metastatic Colorectal Cancer.

New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MRD negativity rates in transplant-ineligible NDMM patients versus VRd alone New detailed results from ...

Paris, December 9, 2024. New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients ...

New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MRD negativity rates in transplant-ineligible NDMM patients versus VRd alone New detailed results from the ...